Freeman and Cowling comment in the Journal of Infectious Diseases on a paper last year by Yang and colleagues (I made a note about that one here). They also re-analysed one of the conclusion and found that, for this dataset at least, having COVID-19 antibodies did not afford a reduced risk of death.
Freeman and Cowling conclude that this doesn't negate using convalescent sera (the bit of blood, minus the cells and the clotting factors, that contain proteins, water and the antibodies we make against an infection we've had) as a treatment option. But from the data in Yang's paper, the pre-infection existence of higher levels of antibodies that react with COVID-19, did not improve chances for survival.
More study is needed.
Subscribe to:
Post Comments (Atom)
-
Click to enlarge. Confirmed CORONA-CoV cases (green) and deaths (red) each week. Case numbers are listed on the y-axis (side), days of each ... -
Map: Approximate Geolocation of A(COVID-19) cases in Eastern China by Flu Season (through January 12, 2014) Map notes: Human infections ... -
#15,090 Invariably, as each country finds that COVID-19 is spreading widely in their communities, local public health efforts will move away...
No comments:
Post a Comment